Treating Gastric Cancer in the Near Future
During the 2022 Gastrointestinal Cancers Symposium, Zev A. Wainberg, MD, predicts how gastric cancer treatment will look in the near future.
Zev A. Wainberg, MD, professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program, provides expert insight on how gastric treatment will evolve over the next 5 years.
Transcription:
0:08 |That's a good question. I think gastric cancer is going to get increasingly subdivided into smaller groups. I think we already know now, that HER2, MSS, or MSI should stay, And CPS you know, those are, I'd say validated biomarkers. We have a few more on the way hopefully with FGFR2B, and also claudin18, and hopefully others beyond that.
0:31 | So, I think, you know, what we'll expect to see over the next few years is more some dividing of the of the pie, which allows us hopefully to find better outcomes are also going to see better exploration of these drugs probably and beyond frontline settings and into earlier spaces such as adjuvant or neoadjuvant, gastric cancer. So, we do have hopefully a good plan for the next few years to develop new drugs and this, you know, terribly unmet need.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
